Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7393096 | 0.92 | HTR2A (0.37) | MEN1KMT2ASMN1; SMN2HPGDNPC1 | |
| SCHEMBL25585 | 0.79 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL2882191 | 0.78 | CA2 (0.43) | SMN1; SMN2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL5732606 | 0.78 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31545933 | 0.77 | MDM2 (0.36) | SMN1; SMN2NPC1RAB9AMAPTPOLB | |
| Methyl Alcohol SCHEMBL28286625 | 0.76 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1HPGDRAB9APOLB | |
| SCHEMBL12419367 | 0.76 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL15371049 | 0.76 | ALDH1A1 (0.42) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL448797 | 0.75 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1HPGDRAB9APOLB | |
| SCHEMBL3950950 | 0.73 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1HPGDRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066337-A | 5-hydroxypyrimidine-4-carboxamide compounds | DAIICHI SANKYO CO LTD | 2011-05-18 | — | — | CN | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | MEN1 2513/4885KMT2A 415/4885SMN1; SMN2 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.